|
|
|
|
NAVIGATOR shows valsartan delayed progression to type 2 diabetes in at-risk cardiovascular patien...
Novartis announces USD 5 billion bond issue Shareholders approve all proposed resolutions of Novartis Board of Directors Novartis receives FDA approval of Menveo, a vaccine to prevent meningococcal di...Novartis oral multiple sclerosis development compound...
|
|
|
Novartis announces USD 5 billion bond issue
chapeau keolis propestus ils y en a mais pour avoir un horaire il y en a pas pourtant apperament ilsy en a des bus des lignes et surtout des...je suis un utilisateur du systme GAIA en Algrie et j'ai suivi une formation de support technique je voudrais bien...
|
|
|
Shareholders approve all proposed resolutions of Novartis Board of Directors
Novartis receives FDA approval of Menveo, a vaccine to prevent meningococcal di...Novartis oral multiple sclerosis development compound Gilenia* (FTY720) granted... Novartis drug Tasigna receives FDA priority review for newly diagnosed patients...
|
|
|
Novartis drug Tasigna receives FDA priority review for newly diagnosed patients with early-stage chronic myelo
how Tasigna exceeds Glivecin every measure of efficacy in the trial including prevention of disease progression at 12 months23 Feb 2010 - Novartis announced that Tasigna (nilotinib) has been granted priority review by the US Food and Drug...
|
|
|
Novartis Drug Tasigna(R) Receives FDA Priority Review for Newly Diagnosed Patients With Early-Stage
Novartis announced today that Tasigna (nilotinib) 200 mg capsules has been granted priority review by the US Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid...
|
|
|
NICE approves Yondelis
Cancer drug Yondelis has been approved by NICE for use on the NHS, but only after the manufacturer offered to meet the cost of anyone needing more than five cycles.NICE had originally said the cost was too high a complaint it made this month about three...
|
|
|
Novartis drug Tasigna receives FDA priority review for newly diagnosed patients with early-stage chronic myeloid leukemia ..
Novartis International AG / Novartis drug Tasigna receives FDA priority review for newly diagnosed patients with early-stage chronic myeloid leukemia processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this...
|
|
|
Novartis drug Tasigna receives FDA priority review for newly diagnosed patients with ...
* Study results show Tasigna exceeds Glivec in every measure of efficacy in the trial including prevention of disease progression at 12 months[1] * Regulatory applications underway worldwide for Tasigna in the first-line indication with submissions...
|
|
|
2/22/10 - Novartis obtains FDA priority review for leukemia drug
(Datamonitor via COMTEX) Novartis, a Swiss pharmaceutical company, has reported that Tasigna 200mg capsules has been granted priority review by the FDA for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic...
|
|
|
Novartis obtains FDA priority review for leukemia drug
(Datamonitor via COMTEX) Novartis, a Swiss pharmaceutical company, has reported that Tasigna 200mg capsules has been granted priority review by the FDA for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic...
|
|
|
Novartis obtains FDA priority review for leukemia drug
(Datamonitor via COMTEX) -- Novartis, a Swiss pharmaceutical company, has reported that Tasigna 200mg capsules has been granted priority review by the FDA for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic...
|
|
|
Novartis obtains FDA priority review for leukemia drug - Zibb.com
Company: Novartis AG (NVS) Novartis, a Swiss pharmaceutical company, has reported that Tasigna 200mg capsules has been granted priority review by the FDA for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic...
|
|
|
Novartis obtains FDA priority review for leukemia drug
Novartis, a Swiss pharmaceutical company, has reported that Tasigna 200mg capsules has been granted priority review by the FDA for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia, or Ph+ CML,...
|
|
|
Novartis' Great Weekend
Lots of news on the pharma front this weekend.Even as GlaxoSmithkline got slammed with a new Congressional investigation Avandia, Novartis quietly had a good weekend. It snared a fast six-month priority review for both its multiple sclerosis drug and a new...
|
|
|
Novartis' Great Weekend
Lots of news on the pharma front this weekend.Even as GlaxoSmithkline got slammed with a new Congressional investigation Avandia, Novartis quietly had a good weekend. It snared a fast six-month priority review for both its multiple sclerosis drug and a new...
|
|
|
Novartis drug Tasigna receives FDA priority review for newly diagnosed patients with early-stage chronic myeloid leukemia
Novartis announced today that Tasigna (nilotinib) has been granted priority review by the US Food and Drug Administration for the treatment of adult patients wi Novartis drug Tasigna receives FDA priority review for newly diagnosed patients with...
|
|
|
Novartis oral multiple sclerosis development compound Gilenia* (FTY720) granted US priority revi...
Novartis drug Tasigna receives FDA priority review for newly diagnosed patients with early-stage chronic myeloid leukemia Toutes les actualits Le travail des seniors est un vaste sujet et plus prcisment le retour l'emploi des seniors.Moi mme je suis ag de...
|
|
|
Novartis obtains FDA priority review for leukemia drug
Novartis, a Swiss pharmaceutical company, has reported that Tasigna 200mg capsules has been granted priority review by the FDA for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia, or Ph+ CML,...
|
|
|
Novartis receives FDA approval of Menveo, a vaccine to prevent meningococcal disease
You are here : Home > Finance > News > Novartis receives FDA approval of Menveo[...] Envoyer un ami Novartis oral multiple sclerosis development compound Gilenia* (FTY720) granted...Novartis drug Tasigna receives FDA priority review for newly...
|
|
|
Novartis gets US approval for meningitis vaccine
Novartis leukemia drug gets faster FDA review Novartis AG said Friday its leukemia drug candidate Tasigna received priority review by the Food and Drug Administration.The special designation speeds up the regulatory review process to six months from...
|
|
|
Novartis Drug Tasigna(R) Receives FDA Priority Review for Newly Diagnosed Patients With Early-Stage Chronic My
EAST HANOVER, N.J., Feb.19 (HSMN NewsFeed) -- Novartis announced today that Tasigna (nilotinib) 200 mg capsules has been granted priority review by the US Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed...
|
|
|
Novartis leukemia drug gets faster FDA review
NEW YORK (AP) - Novartis AG said Friday its leukemia drug candidate Tasigna received priority review by the Food and Drug Administration.Novartis leukemia drug gets faster FDA review.
|
|
|
2/19/10 - Novartis drug Tasigna receives FDA priority review for newly diagnosed patients with early-stage
Novartis drug Tasigna receives FDA priority review for newly diagnosed patients with early-stage chronic myeloid leukemia - February 19, 2010 Pharmacy Article 2/19/10 - Novartis drug Tasigna receives FDA priority review for newly diagnosed patients...
|
|
|
Novartis Drug Tasigna Receives FDA Priority Review For Newly Diagnosed Patients With Early-stage Chronic Myel
Novartis Drug Tasigna Receives FDA Priority Review For Newly Diagnosed Patients With Early-stage Chronic Myeloid Leukemia20 Feb 2010 Novartis announced that Tasigna (nilotinib) has been granted priority review by the US Food and Drug Administration ...
|
|
|
Novartis Drug Tasigna Receives FDA Priority Review For Newly Diagnosed Patients With Early-stage Chronic Myeloid Leukemia
Novartis Drug Tasigna Receives FDA Priority Review For Newly Diagnosed Patients With Early-stage Chronic Myeloid Leukemia20 Feb 2010 Novartis announced that Tasigna (nilotinib) has been granted priority review by the US Food and Drug Administration ...
|
